Management of opioid-induced nausea and vomiting in cancer patients: Systematic review and evidence-based recommendations

Palliative Medicine

Volumn 25, Issue 5, 2011, Pages 442-453

  Laugsand, Eivor A ^a   Kaasa, Stein ^a,b   Klepstad, Pål ^b,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

adverse effects; emesis; Neoplasm; opioids; pain; palliative care; symptoms

Indexed keywords

AMITRIPTYLINE; BUPRENORPHINE; CHLORPROMAZINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; KETAMINE; METHADONE; METOCLOPRAMIDE; MORPHINE; OLANZAPINE; ONDANSETRON; OPIATE; OXYCODONE; PLACEBO; SCOPOLAMINE; SULPIRIDE; THIETHYLPERAZINE; TROPISETRON; VALPROIC ACID;

CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CONFERENCE PAPER; DELIRIUM; DROWSINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; OPIOID INDUCED EMESIS; OPIOID INDUCED NAUSEA; OPIOID INDUCED NAUSEA AND VOMITING; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ANTIEMETICS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; NAUSEA; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 79959917069     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216311404273     Document Type: Conference Paper

References (79)

1. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007 ; 34: 94-104 (Pubitemid 46970881)
2. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994 ; 3: 183-189 (Pubitemid 24253426)
3. Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Support Care Canc. 2000 ; 8: 444-452
4. Johnsen AT, Petersen MA, Pedersen L, Groenvold M. Symptoms and problems in a nationally representative sample of advanced cancer patients. Palliat Med. 2009 ; 23: 491-501
5. Laugsand EA, Kaasa S, de Conno F, Hanks G, Klepstad P. Intensity and treatment of symptoms in 3,030 palliative care patients: a cross-sectional survey of the EAPC Research Network. J Opioid Manag. 2009 ; 5: 11-21
6. Hursti TJ, Avall-Lundqvist E, Borjeson S, et al. Impact of tumour burden on chemotherapy-induced nausea and vomiting. Br J Canc. 1996 ; 74: 1114-1119 (Pubitemid 26333916)
7. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage. 1996 ; 12: 3-10 (Pubitemid 26187518)
8. Feyer PC, Stewart AL, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Support Care Canc. 1998 ; 6: 253-260 (Pubitemid 28213062)
9. Foubert J, Vaessen G. Nausea: the neglected symptom?. Eur J Oncol Nurs. 2005 ; 9: 21-32 (Pubitemid 40361583)
10. Mercadante S, Villari P, Ferrera P, Casuccio A. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?. Eur J Pain. 2006 ; 10: 153-159 (Pubitemid 41727765)
11. Campora E, Merlini L, Pace M, et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage. 1991 ; 6: 428-430
12. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001 ; 111 (Suppl 8A). 106S - 112S (Pubitemid 34032001)
13. Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci. 2006 ; 129: 3-16 (Pubitemid 44472635)
14. Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life: 'I was feeling nauseous all of the time ... nothing was working'. J Am Med Assoc. 2007 ; 298: 1196-1207 (Pubitemid 47403106)
15. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995 ; 10: 378-384
16. Bruera E, Kim HN. Cancer pain. J Am Med Assoc. 2003 ; 290: 2476-2479 (Pubitemid 37430548)
17. Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain. 2008 ; 24 (Suppl 10). S8 - S13
18. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006 ; 74: 1347-1354 (Pubitemid 44607306)
19. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. Br Med J. 2004 ; 328: 1490-1490
20. Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst. 2006 ; 4: 21-21
21. Kaasa S, Loge JH, Fayers P, et al. Symptom assessment in palliative care: a need for international collaboration. J Clin Oncol. 2008 ; 26: 3867-3873
22. Athanassiadis C, Karamanis A. Akathisia after long-term epidural use of droperidol: a case report. Pain. 1992 ; 50: 203-204
23. Ferris FD, Kerr IG, Sone M, Marcuzzi M. Clinical note. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom Manage. 1991 ; 6: 389-393
24. Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Canc. 2002 ; 10: 231-236 (Pubitemid 36056297)
25. Mercadante S, Sapio M, Serretta R. Ondansetron in nausea and vomiting induced by spinal morphine. J Pain Symptom Manage. 1998 ; 16: 259-262 (Pubitemid 28478240)
26. Okamoto Y, Tsuneto S, Matsuda Y, et al. A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage. 2007 ; 34: 217-222 (Pubitemid 47096780)
27. Yomiya K, Narita M, Kuzumaki N, Takei D, Suzuki T and Matoba M. Usefulness of peropirone for the prevention of nausea related to opioid administration. Vienna: The European Association for Palliative Care, 2009.
28. Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage. 1994 ; 9: 48-50 (Pubitemid 24061826)
29. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003 ; 6: 251-255 (Pubitemid 36538899)
30. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol. 2001 ; 19: 2542-2554 (Pubitemid 32391226)
31. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003 ; 4: 231-256 (Pubitemid 36807905)
32. Rogers AG. When all oral opioids cause nausea and vomiting. J Pain Symptom Manage. 1988 ; 3: 114-114
33. Corli O, Cozzolino A, Battaiotto L. Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. J Pain Symptom Manage. 1995 ; 10: 521-526
34. Takahashi H. Effects of acupuncture on terminal cancer patients in the home care setting. Med Acupuncture. 2009 ; 21: 123-129
35. Bruera ED, MacEachern TJ, Spachynski KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 1994 ; 74: 3204-3211 (Pubitemid 24375078)
36. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000 ;: 427-435 (Pubitemid 30447368)
37. Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage. 2004 ; 28: 381-388 (Pubitemid 39313167)
38. Eisenchlas JH, Garrigue N, Junin M, De Simone GG. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med. 2005 ; 19: 71-75 (Pubitemid 40202061)
39. Morita T, Tei Y, Shishido H, Inoue S. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage. 2004 ; 28: 102-103 (Pubitemid 38970072)
40. Muir JC, von Gunten CF. Abdominal cancer, nausea, and vomiting. J Palliat Med. 2001 ; 4: 391-394 (Pubitemid 32937521)
41. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998 ; 83: 1214-1223 (Pubitemid 28419076)
42. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manage. 1998 ; 15: 176-184 (Pubitemid 28169140)
43. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002 ; 23: 526-532 (Pubitemid 34627037)
44. Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. 2002 ; 23: 60-65 (Pubitemid 34093884)
45. Lightfoot T, Muirden N. Mexiletine as a treatment for malignant neuropathic pain. Aust New Zeal J Med. 1998 ; 28: 664-664
46. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage. 1995 ; 10: 564-568
47. Ross JR, Goller K, Hardy J, et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med. 2005 ; 8: 1118-1126 (Pubitemid 43010543)
48. Vranken JH, Van der Vegt MH, Zuurmond WWA, Pijl AJ, Dzoljic M. Continuous brachial plexus block at the cervical level using a posterior approach in the management of neuropathic cancer pain. Region Anesth Pain M. 2001 ; 26: 572-575 (Pubitemid 33065136)
49. Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage. 2001 ; 22: 627-630 (Pubitemid 32725801)
50. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage. 1999 ; 18: 174-179 (Pubitemid 29459122)
51. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997 ; 73: 37-45 (Pubitemid 27470824)
52. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990 ; 47: 639-646 (Pubitemid 20190103)
53. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain. 1998 ; 2: 53-62 (Pubitemid 28248320)
54. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage. 1996 ; 12: 182-189 (Pubitemid 26269244)
55. Marinangeli F, Ciccozzi A, Aloisio L, et al. Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Pain Pract. 2007 ; 7: 307-312 (Pubitemid 350142299)
56. Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005 ; 23: 5229-5234 (Pubitemid 46224034)
57. Mystakidou K, Tsilika E, Parpa E, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Canc. 2003 ; 107: 486-492 (Pubitemid 37266471)
58. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. Front Biosci. 2007 ; 12: 1291-1299 (Pubitemid 46846834)
59. Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage. 2008 ; 36: 117-125 (Pubitemid 352010492)
60. Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage. 1998 ; 16: 102-111 (Pubitemid 28400160)
61. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996 ; 67: 115-119 (Pubitemid 26319643)
62. Wirz S, Wartenberg HC, Elsen C, Wittmann M, Diederichs M, Nadstawek J. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial. Clin J Pain. 2006 ; 22: 770-775 (Pubitemid 44627439)
63. Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Canc. 2008 ; 16: 999-1009
64. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009 ; 13: 737-743
65. Babul N, Provencher L, Laberge F, Harsanyi Z, Moulin D. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol. 1998 ; 38: 74-81 (Pubitemid 28086727)
66. Bruera E, Fainsinger R, Spachynski K, Babul N, Harsanyi Z, Darke AC. Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J Clin Oncol. 1995 ; 13: 1520-1527
67. De Conno F, Ripamonti C, Saita L, MacEachern T, Hanson J, Bruera E. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol. 1995 ; 13: 1004-1008
68. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain. 1989 ; 36: 169-176 (Pubitemid 19045575)
69. McDonald P, Graham P, Clayton M, Buhagiar A, Stuart-Harris R. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med. 1991 ; 5: 323-329
70. Bruera E, Belzile M, Neumann CM, Ford I, Harsanyi Z, Darke A. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial. Support Care Canc. 1999 ; 7: 280-283 (Pubitemid 29302637)
71. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995 ; 76: 1283-1293
72. Fukui T, Takashi O, Rahman M, et al. Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan. Jpn Med Assoc J. 2005 ; 48: 216-223 (Pubitemid 41007480)
73. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage. 1991 ; 6: 125-128
74. Klepstad P, Borchgrevink PC, Dale O, et al. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med. 2003 ; 17: 679-687 (Pubitemid 37508952)
75. Mercadante S, Calderone L, Villari P, et al. The use of pilocarpine in opioid-induced xerostomia. Palliat Med. 2000 ; 14: 529-531
76. Minotti V, Patoia L, Roila F, et al. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain. 1989 ; 36: 177-183 (Pubitemid 19045576)
77. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002 ; 23: 442-447 (Pubitemid 34463013)
78. Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 2010 ; 39: 756-767
79. Tassinari D. Surrogate end points of quality of life assessment: have we really found what we are looking for?. Health Qual Life Outcomes. 2003 ; 1: 71-71